Petitclerc E - Search Results

1

Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin.

Bérubé M, Talbot M, Collin C, Paquet-Bouchard C, Germain L, Guérin SL, Petitclerc E. Bérubé M, et al. Among authors: petitclerc e. Int J Oncol. 2005 Feb;26(2):405-13. Int J Oncol. 2005. PMID: 15645125 Free article.

2

MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment.

Bérubé M, Deschambeault A, Boucher M, Germain L, Petitclerc E, Guérin SL. Bérubé M, et al. Among authors: petitclerc e. Mol Vis. 2005 Dec 14;11:1101-11. Mol Vis. 2005. PMID: 16379022 Free article.

3

Loss of function of vascular smooth muscle cells by nitric oxide-dependent and -independent interactions with tumorigenic cells.

Morissette G, Petitclerc E, Marceau F. Morissette G, et al. Among authors: petitclerc e. Int J Cancer. 2004 Dec 10;112(5):830-9. doi: 10.1002/ijc.20495. Int J Cancer. 2004. PMID: 15386369

4

Microtubule-destabilizing agents induce focal adhesion structure disorganization and anoikis in cancer cells.

Deschesnes RG, Patenaude A, Rousseau JL, Fortin JS, Ricard C, Côté MF, Huot J, C-Gaudreault R, Petitclerc E. Deschesnes RG, et al. Among authors: petitclerc e. J Pharmacol Exp Ther. 2007 Feb;320(2):853-64. doi: 10.1124/jpet.106.110957. Epub 2006 Nov 10. J Pharmacol Exp Ther. 2007. PMID: 17099073

5

Kinin receptors: functional aspects.

Marceau F, Sabourin T, Houle S, Fortin JP, Petitclerc E, Molinaro G, Adam A. Marceau F, et al. Among authors: petitclerc e. Int Immunopharmacol. 2002 Dec;2(13-14):1729-39. doi: 10.1016/s1567-5769(02)00189-3. Int Immunopharmacol. 2002. PMID: 12489786 Review.

6

Vascular smooth muscle contractility assays for inflammatory and immunological mediators.

Marceau F, deBlois D, Petitclerc E, Levesque L, Drapeau G, Audet R, Godin D, Larrivée JF, Houle S, Sabourin T, Fortin JP, Morissette G, Gera L, Bawolak MT, Koumbadinga GA, Bouthillier J. Marceau F, et al. Among authors: petitclerc e. Int Immunopharmacol. 2010 Nov;10(11):1344-53. doi: 10.1016/j.intimp.2010.08.016. Epub 2010 Sep 8. Int Immunopharmacol. 2010. PMID: 20831918 Free article. Review.

7

Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.

Petitclerc E, Deschesnes RG, Côté MF, Marquis C, Janvier R, Lacroix J, Miot-Noirault E, Legault J, Mounetou E, Madelmont JC, C -Gaudreault R. Petitclerc E, et al. Cancer Res. 2004 Jul 1;64(13):4654-63. doi: 10.1158/0008-5472.CAN-03-3715. Cancer Res. 2004. PMID: 15231678

8

Chloroethyl urea derivatives block tumour growth and thioredoxin-1 nuclear translocation.

Patenaude A, Fortin JS, Deschenes R, Côté MF, Lacroix J, C-Gaudreault R, Petitclerc E. Patenaude A, et al. Among authors: petitclerc e. Can J Physiol Pharmacol. 2010 Nov;88(11):1102-14. doi: 10.1139/y10-084. Can J Physiol Pharmacol. 2010. PMID: 21076498

9

Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival.

Petitclerc E, Strömblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, Cheresh DA, Brooks PC. Petitclerc E, et al. Cancer Res. 1999 Jun 1;59(11):2724-30. Cancer Res. 1999. PMID: 10363998

10

C5a receptor antagonism coming of age for vascular pathology.

Marceau F, Petitclerc E. Marceau F, et al. Among authors: petitclerc e. Int Immunopharmacol. 2022 Sep;110:109042. doi: 10.1016/j.intimp.2022.109042. Epub 2022 Jul 14. Int Immunopharmacol. 2022. PMID: 35843145

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters